中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

药物性肝损伤的临床表现和分型

杨婉娜,  谢雯

PDF下载 ( 1907 KB)
文章导航 > 临床肝胆病杂志  > 2021 >  37(11): 2525-2529
陈小青, 任俞霏, 孔维宗, 王迎春. 丹酚酸B对非酒精性脂肪性肝病细胞模型氧化应激的影响[J]. 临床肝胆病杂志, 2018, 34(10): 2175-2181. DOI: 10.3969/j.issn.1001-5256.2018.10.022.
引用本文: 陈小青, 任俞霏, 孔维宗, 王迎春. 丹酚酸B对非酒精性脂肪性肝病细胞模型氧化应激的影响[J]. 临床肝胆病杂志, 2018, 34(10): 2175-2181. DOI: 10.3969/j.issn.1001-5256.2018.10.022.
shu
Chen XiaoQing, Ren YuFei, Kong WeiZong, Wang YingChun. Effect of salvianolic acid B on oxidative stress in a cell model of nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2018, 34(10): 2175-2181. DOI: 10.3969/j.issn.1001-5256.2018.10.022.
Citation: Chen XiaoQing, Ren YuFei, Kong WeiZong, Wang YingChun. Effect of salvianolic acid B on oxidative stress in a cell model of nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2018, 34(10): 2175-2181. DOI: 10.3969/j.issn.1001-5256.2018.10.022.
shu

药物性肝损伤的临床表现和分型

DOI: 10.3969/j.issn.1001-5256.2021.11.004

  • 首都医科大学附属北京地坛医院 肝病中心，北京 100015

基金项目: 

肝病创新药物早期临床试验关键技术规范研究 (Z191100007619037);

北京市示范性研究型病房 (BCRW202007)

详细信息
    通信作者:

    谢雯，xiewen6218@163.com

  • 中图分类号: R575

Clinical manifestations and typing of drug-induced liver injury

  • Center of Liver Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China

Research funding: 

The Key Technical and Executive Measures to Improve Early Phase Clinical Trials on Innovative Drugs for Liver Diseases (Z191100007619037);

Beijing Demonstration Research Ward (BCRW202007)

摘要

    摘要
  • 摘要: 药物性肝损伤是人体最常见和最严重的药物不良反应之一，部分严重者会出现肝衰竭甚至死亡。不同药物所致肝损伤的临床表现各异，严重程度不尽相同，大多数药物性肝损伤患者没有症状或症状较轻。根据临床表现、病程和发病机制，可将药物性肝损伤进行多种分型。根据R值，可进行如下临床分型：肝细胞损伤型(R≥5)；胆汁淤积型(R≤2)；混合型(2＜R＜5)。根据病程，药物性肝损伤可分为急性药物性肝损伤和慢性药物性肝损伤。根据发病机制，药物性肝损伤可分为固有型、特异质型和间接损伤型。全面了解药物性肝损伤的临床表现和分型方式，有助于揭示其发病机制，以及时诊断和治疗药物性肝损伤。

     

    Abstract: Drug-induced liver injury (DILI) is one of the most common and severe adverse drug reactions in humans, which may lead to liver failure and even death in some patients. Liver injury caused by different drugs has various clinical manifestations and severities, and most patients with DILI have no symptoms or have mild symptoms. There are various typing methods for DILI based on clinical features, course of disease, and pathogenesis. According to the R value, DILI can be classified into hepatocellular injury type (R ≥5), cholestasis type (R ≤2), and mixed type (2 < R < 5); according to the course of the disease, DILI can be classified into acute DILI and chronic DILI; according to the pathogenesis, DILI can be classified into intrinsic DILI, idiosyncratic DILI, and indirect DILI. A comprehensive understanding of the clinical manifestations and typing methods of DILI helps to reveal its pathogenesis and perform diagnosis and treatment in a timely manner.

     

    • HTML全文
    • 参考文献(51)
  • [1] Drug-induced Liver Disease Study Group, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the management of drug-induced liver injury[J]. J Clin Hepatol, 2015, 31(11): 1752-1769. DOI: 10.3969/j.issn.1001-5256.2015.11.002.

    中华医学会肝病学分会药物性肝病学组. 药物性肝损伤诊治指南[J]. 临床肝胆病杂志, 2015, 31(11): 1752-1769. DOI: 10.3969/j.issn.1001-5256.2015.11.002.
    [2] OSTAPOWICZ G, FONTANA RJ, SCHIØDT FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States[J]. Ann Intern Med, 2002, 137(12): 947-954. DOI: 10.7326/0003-4819-137-12-200212170-00007.
    [3] DAVERN TJ. Drug-induced liver disease[J]. Clin Liver Dis, 2012, 16(2): 231-245. DOI: 10.1016/j.cld.2012.03.002.
    [4] CHALASANI NP, HAYASHI PH, BONKOVSKY HL, et al. ACG Clinical Guideline: The diagnosis and management of idiosyncratic drug-induced liver injury[J]. Am J Gastroenterol, 2014, 109(7): 950-966; quiz 967. DOI: 10.1038/ajg.2014.131.
    [5] CHALASANI N, BONKOVSKY HL, FONTANA R, et al. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN prospective study[J]. Gastroenterology, 2015, 148(7): 1340-1352. e7. DOI: 10.1053/j.gastro.2015.03.006.
    [6] KLEINER DE, CHALASANI NP, LEE WM, et al. Hepatic histological findings in suspected drug-induced liver injury: Systematic evaluation and clinical associations[J]. Hepatology, 2014, 59(2): 661-670. DOI: 10.1002/hep.26709.
    [7] AITHAL PG, DAY CP. The natural history of histologically proved drug induced liver disease[J]. Gut, 1999, 44(5): 731-735. DOI: 10.1136/gut.44.5.731.
    [8] ANDRADE RJ, LUCENA MI, KAPLOWITZ N, et al. Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry[J]. Hepatology, 2006, 44(6): 1581-1588. DOI: 10.1002/hep.21424.
    [9] AITHAL GP, WATKINS PB, ANDRADE RJ, et al. Case definition and phenotype standardization in drug-induced liver injury[J]. Clin Pharmacol Ther, 2011, 89(6): 806-815. DOI: 10.1038/clpt.2011.58.
    [10] MEDINA-CALIZ I, ROBLES-DIAZ M, GARCIA-MUÑOZ B, et al. Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury[J]. J Hepatol, 2016, 65(3): 532-542. DOI: 10.1016/j.jhep.2016.05.003.
    [11] EASL Clinical Practice Guidelines: Drug-induced liver injury[J]. J Hepatol, 2019, 70(6): 1222-1261. DOI: 10.1016/j.jhep.2019.02.014.
    [12] LARSON AM, POLSON J, FONTANA RJ, et al. Acetaminophen-induced acute liver failure: Results of a United States multicenter, prospective study[J]. Hepatology, 2005, 42(6): 1364-1372. DOI: 10.1002/hep.20948.
    [13] PYE M, NORTHCOTE RJ, COBBE SM. Acute hepatitis after parenteral amiodarone administration[J]. Br Heart J, 1988, 59(6): 690-691. DOI: 10.1136/hrt.59.6.690.
    [14] DALTON TA, BERRY RS. Hepatotoxicity associated with sustained-release niacin[J]. Am J Med, 1992, 93(1): 102-104. DOI: 10.1016/0002-9343(92)90689-9.
    [15] SUÁREZ FERRER C, LLOP HERRERA E, CALVO MOYA M, et al. Idiopathic portal hypertension regarding thiopurine treatment in patients with inflammatory bowel disease[J]. Rev Esp Enferm Dig, 2016, 108(2): 79-83. DOI: 10.17235/reed.2015.3954/2015.
    [16] COTTE L, BÉNET T, BILLIOUD C, et al. The role of nucleoside and nucleotide analogues in nodular regenerative hyperplasia in HIV-infected patients: A case control study[J]. J Hepatol, 2011, 54(3): 489-496. DOI: 10.1016/j.jhep.2010.07.030.
    [17] MALLET V, BLANCHARD P, VERKARRE V, et al. Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients[J]. AIDS, 2007, 21(2): 187-192. DOI: 10.1097/QAD.0b013e3280119e47.
    [18] WANG JJ, CHENG C, XIE W, et al. Analysis on the clinical characteristics of hepatic veno-occlusive disease caused by gynurasegetum for 8 cases[J]. Chin Med Modern Distance Educ of China, 2021, 19(7): 139-142. DOI: 10.3969/j.issn.1672-2779.2021.07.053.

    王京京, 程澄, 谢雯, 等. 土三七致肝窦阻塞综合征8例临床特点分析及文献复习[J]. 中国中医药现代远程教育, 2021, 19(7): 139-142. DOI: 10.3969/j.issn.1672-2779.2021.07.053.
    [19] BATTIPAGLIA G, LABOPIN M, CANDONI A, et al. Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: A retrospective study from the Acute Leukemia Working Party of the EBMT[J]. Bone Marrow Transplant, 2017, 52(4): 592-599. DOI: 10.1038/bmt.2016.302.
    [20] KUMAR S, DELEVE LD, KAMATH PS, et al. Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation[J]. Mayo Clin Proc, 2003, 78(5): 589-598. DOI: 10.4065/78.5.589.
    [21] DELEVE LD, SHULMAN HM, MCDONALD GB. Toxic injury to hepatic sinusoids: Sinusoidal obstruction syndrome (veno-occlusive disease)[J]. Semin Liver Dis, 2002, 22(1): 27-42. DOI: 10.1055/s-2002-23204.
    [22] STEWART JD, HORVATH R, BARUFFINI E, et al. Polymerase γ gene POLG determines the risk of sodium valproate-induced liver toxicity[J]. Hepatology, 2010, 52(5): 1791-1796. DOI: 10.1002/hep.23891.
    [23] MARGOLIS AM, HEVERLING H, PHAM PA, et al. A review of the toxicity of HIV medications[J]. J Med Toxicol, 2014, 10(1): 26-39. DOI: 10.1007/s13181-013-0325-8.
    [24] JONES DB, MULLICK FG, HOOFNAGLE JH, et al. Reye's syndrome-like illness in a patient receiving amiodarone[J]. Am J Gastroenterol, 1988, 83(9): 967-969.
    [25] CULLEN JM. Mechanistic classification of liver injury[J]. Toxicol Pathol, 2005, 33(1): 6-8. DOI: 10.1080/01926230590522428.
    [26] MCKENZIE R, FRIED MW, SALLIE R, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B[J]. N Engl J Med, 1995, 333(17): 1099-1105. DOI: 10.1056/NEJM199510263331702.
    [27] WEI CM, CHEN HL, LEE PI, et al. Reye's syndrome developing in an infant on treatment of Kawasaki syndrome[J]. J Paediatr Child Health, 2005, 41(5-6): 303-304. DOI: 10.1111/j.1440-1754.2005.00617.x.
    [28] ZHANG X, OUYANG J, THUNG SN. Histopathologic manifestations of drug-induced hepatotoxicity[J]. Clin Liver Dis, 2013, 17(4): 547-564, vii-viii. DOI: 10.1016/j.cld.2013.07.004.
    [29] RAMACHANDRAN R, KAKAR S. Histological patterns in drug-induced liver disease[J]. J Clin Pathol, 2009, 62(6): 481-492. DOI: 10.1136/jcp.2008.058248.
    [30] SHEN T, LIU Y, SHANG J, et al. Incidence and etiology of drug-induced liver injury in Mainland China[J]. Gastroenterology, 2019, 156(8): 2230-2241. e11. DOI: 10.1053/j.gastro.2019.02.002.
    [31] CAO XY, XUE M, WEN Y, et al. Research progress on susceptibility genes of anti-tuberculous drug-induced liver injury[J]. Chin J Antituberc, 2021, 43(2): 190-193. DOI: 10.3969/j.issn.1000-6621.2021.02.016.

    曹鑫宇, 薛秒, 文艳, 等. 抗结核药物性肝损伤易感基因研究进展[J]. 中国防痨杂志, 2021, 43(2): 190-193. DOI: 10.3969/j.issn.1000-6621.2021.02.016.
    [32] LUCENA MI, MOLOKHIA M, SHEN Y, et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class Ⅰ and Ⅱ alleles[J]. Gastroenterology, 2011, 141(1): 338-347. DOI: 10.1053/j.gastro.2011.04.001.
    [33] DALY AK, DONALDSON PT, BHATNAGAR P, et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin[J]. Nat Genet, 2009, 41(7): 816-819. DOI: 10.1038/ng.379.
    [34] YANG WN, PANG LL, ZHOU JY, et al. Single-nucleotide polymorphisms of HLA and Polygonum multiflorum-induced liver injury in the Han Chinese population[J]. World J Gastroenterol, 2020, 26(12): 1329-1339. DOI: 10.3748/wjg.v26.i12.1329.
    [35] KARDAUN SH, SIDOROFF A, VALEYRIE-ALLANORE L, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: Does a DRESS syndrome really exist?[J]. Br J Dermatol, 2007, 156(3): 609-611. DOI: 10.1111/j.1365-2133.2006.07704.x.
    [36] BJÖRNSSON ES, BERGMANN OM, BJÖRNSSON HK, et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland[J]. Gastroenterology, 2013, 144(7): 1419-1425. e1-e3; quiz e19-e20. DOI: 10.1053/j.gastro.2013.02.006.
    [37] ZIMMERMAN HJ. Drug-induced liver disease[J]. Clin Liver Dis, 2000, 4(1): 73-96, vi. DOI: 10.1016/s1089-3261(05)70097-0.
    [38] SPEEG KV, BAY MK. Prevention and treatment of drug-induced liver disease[J]. Gastroenterol Clin North Am, 1995, 24(4): 1047-1064.
    [39] GORDON V, ADHIKARY R, APPLEBY V, et al. Diagnosis, presentation and initial severity of Autoimmune Hepatitis (AIH) in patients attending 28 hospitals in the UK[J]. Liver Int, 2018, 38(9): 1686-1695. DOI: 10.1111/liv.13724.
    [40] BJÖRNSSON E, TALWALKAR J, TREEPRASERTSUK S, et al. Drug-induced autoimmune hepatitis: Clinical characteristics and prognosis[J]. Hepatology, 2010, 51(6): 2040-2048. DOI: 10.1002/hep.23588.
    [41] LICATA A, MAIDA M, CABIBI D, et al. Clinical features and outcomes of patients with drug-induced autoimmune hepatitis: A retrospective cohort study[J]. Dig Liver Dis, 2014, 46(12): 1116-1120. DOI: 10.1016/j.dld.2014.08.040.
    [42] BJÖRNSSON ES, BERGMANN O, JONASSON JG, et al. Drug-induced autoimmune hepatitis: Response to corticosteroids and lack of relapse after cessation of steroids[J]. Clin Gastroenterol Hepatol, 2017, 15(10): 1635-1636. DOI: 10.1016/j.cgh.2017.05.027.
    [43] CZAJA AJ. Difficult treatment decisions in autoimmune hepatitis[J]. World J Gastroenterol, 2010, 16(8): 934-947. DOI: 10.3748/wjg.v16.i8.934.
    [44] HOOFNAGLE JH, BJÖRNSSON ES. Drug-induced liver injury - types and phenotypes[J]. N Engl J Med, 2019, 381(3): 264-273. DOI: 10.1056/NEJMra1816149.
    [45] PEERAPHATDIT TB, WANG J, ODENWALD MA, et al. Hepatotoxicity from immune checkpoint inhibitors: A systematic review and management recommendation[J]. Hepatology, 2020, 72(1): 315-329. DOI: 10.1002/hep.31227.
    [46] AFFOLTER T, LLEWELLYN HP, BARTLETT DW, et al. Inhibition of immune checkpoints PD-1, CTLA-4, and IDO1 coordinately induces immune-mediated liver injury in mice[J]. PLoS One, 2019, 14(5): e0217276. DOI: 10.1371/journal.pone.0217276.
    [47] de MARTIN E, MICHOT JM, PAPOUIN B, et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors[J]. J Hepatol, 2018, 68(6): 1181-1190. DOI: 10.1016/j.jhep.2018.01.033.
    [48] INAMORI O, MIYAGAWA-HAYASHINO A, UENO A, et al. Fulminant hepatitis as an immune-related adverse event after nivolumab treatment[J]. Pathol Int, 2019, 69(7): 434-436. DOI: 10.1111/pin.12812.
    [49] ROOKS JB, ORY HW, ISHAK KG, et al. Epidemiology of hepatocellular adenoma. The role of oral contraceptive use[J]. JAMA, 1979, 242(7): 644-648.
    [50] BARTHELMES L, TAIT IS. Liver cell adenoma and liver cell adenomatosis[J]. HPB (Oxford), 2005, 7(3): 186-196. DOI: 10.1080/13651820510028954.
    [51] VELAZQUEZ I, ALTER BP. Androgens and liver tumors: Fanconi's anemia and non-Fanconi's conditions[J]. Am J Hematol, 2004, 77(3): 257-267. DOI: 10.1002/ajh.20183.
    • 相关文章
    • 施引文献

  • 期刊类型引用(31)

    1. 丁辉，苏雪梅，张蓉. 子宫内膜异位症患者血清GP73和SMAD2表达水平及临床价值研究. 现代检验医学杂志. 2025(01): 122-126+131 . 百度学术
    2. 王慧敏，谭炳芹，王万鹏，吴梦雪. 慢性乙型肝炎病毒感染相关肝病患者血清高尔基体蛋白73水平变化分析. 山东医药. 2025(01): 100-103+108 . 百度学术
    3. 张璨，张欢欢，高飞，任佩佩，罗明阳，闫冬，王馨，王莹莹，曾艳丽. 血清高尔基体蛋白73联合肝脏硬度评估慢性乙型肝炎病毒感染患者肝纤维化进展的价值. 中华实用诊断与治疗杂志. 2024(10): 1013-1018 . 百度学术
    4. 李述美，刘冰，刘仁伟，杨洁. GP73、IL-2R、miR-21预测慢性乙肝患者显著肝纤维化的临床价值. 重庆医学. 2024(23): 3575-3580 . 百度学术
    5. 安薪宇，乔杰，胡灵溪，王荣琦，南月敏. GP73对慢性肝病患者肝纤维化诊断价值的研究. 中华内科杂志. 2023(01): 49-53 . 百度学术
    6. 张航，刘近春. 血清高尔基体蛋白73在非酒精性脂肪性肝病中的作用. 临床肝胆病杂志. 2023(03): 657-662 . 本站查看
    7. 马杨青，范海纳，孙鑫，刘成海. 高尔基体蛋白73(GP73)对慢性肝病的诊断价值. 临床肝胆病杂志. 2023(08): 1999-2004 . 本站查看
    8. 张欢，雷学忠. 新型血清标志物高尔基体蛋白73在慢性乙型肝炎临床诊治中的研究进展. 华西医学. 2023(08): 1243-1246 . 百度学术
    9. 陈腾千，姜丽华，张生君，蒋义贵，罗佳，胡永敏，尤丽财. 高尔基体蛋白73在非酒精性脂肪性肝病中的应用价值. 黑龙江医学. 2023(17): 2053-2055+2059 . 百度学术
    10. 李雨蓉，姚明解，王杰. 序贯无创检测提高肝纤维化筛查效率. 肝脏. 2023(10): 1146-1149 . 百度学术
    11. 刘燕娜，姚明解，郑素军，陈香梅，刘向祎，胡鹏，欧启水，窦晓光，陈红松，段钟平，侯金林，南月敏，高志良，徐小元，庄辉，鲁凤民. 血清高尔基体蛋白73在慢性肝病患者中的临床应用. 中华肝脏病杂志. 2022(01): 4-8 . 百度学术
    12. 裴倩云，孙颖. 血清免疫球蛋白检验在肝衰竭患者的诊断价值. 系统医学. 2022(15): 103-105+118 . 百度学术
    13. 王鹏飞，刘树红，钱相君，翟相威，文夏杰，姚明解，赵景民，鲁凤民. 血清高尔基体蛋白73对丙型肝炎肝硬化的诊断价值研究. 中华肝脏病杂志. 2022(08): 879-884 . 百度学术
    14. 郑伟明，罗翠转，卢金英，骆晓豪，刘浩，梁栋伟. 血过氧化物酶增殖体激活受体γ与慢性乙型肝炎患者炎症的相关性. 中国肝脏病杂志(电子版). 2022(04): 42-47 . 百度学术
    15. 庄云英，张海燕，曾清芳. 慢性乙型肝炎肝纤维化的无创诊断研究进展. 肝脏. 2021(01): 84-87 . 百度学术
    16. 刘燕娜，姚明解，鲁凤民. 慢性肝病患者中血清高尔基体蛋白73的临床应用. 肝脏. 2021(02): 103-106 . 百度学术
    17. Application of serum Golgi protein-73 in the management of chronic liver disease. 中华医学杂志英文版. 2021(07): 777-779 . 百度学术
    18. 罗双艳，何颖. 慢性乙肝患者肝脏炎症及纤维化的影响因素及其与血清高尔基体蛋白73的相关性. 医学信息. 2021(15): 5-8 . 百度学术
    19. 高伟，高虹，尹春梅，杨森林，范晓红，刘春亮，李雪卿，贾妮娜. 血清GP73与p62测定对HBV相关慢加急性肝衰竭患者短期预后的预测价值比较. 中华肝脏病杂志. 2021(09): 855-860 . 百度学术
    20. 王一奇，苑喜微，李冬冬，汤玉会，薛宁宁，崔璐瑶，刘领弟，南月敏. 血浆高尔基体蛋白73及相关模型诊断非酒精性脂肪性肝病的研究. 中华肝脏病杂志. 2021(12): 1170-1176 . 百度学术
    21. 张春林. 患儿脓毒症继发肝损伤的危险因素及血清高尔基体跨膜糖蛋白73、微小RNA-122a水平变化. 中国临床医生杂志. 2020(02): 236-238 . 百度学术
    22. 刘沁雨，常越，张青，丁玉平，李海. 高尔基体蛋白73对抗病毒治疗慢性乙型肝炎患者代偿期肝硬化的诊断价值. 解放军医药杂志. 2020(03): 86-91 . 百度学术
    23. 翟相威，刘树红，姚明解，钱相君，文夏杰，许强，赵景民，鲁凤民. 基于血清高尔基体蛋白73的代偿期乙型肝炎肝硬化无创诊断模型的建立及初步应用. 中华肝脏病杂志. 2020(01): 47-52 . 百度学术
    24. 范旭，单珊，刘立伟，贾继东. 血清高尔基糖蛋白73优于APRI、FIB-4对慢性HBV感染患者显著纤维化的诊断. 现代消化及介入诊疗. 2020(04): 529-532 . 百度学术
    25. 范旭，单珊，刘立伟，贾继东. 血清高尔基体跨膜糖73蛋白及其他生物标志物联合检测在AFP阴性小肝癌诊断中的意义. 现代消化及介入诊疗. 2020(04): 435-439+443 . 百度学术
    26. 刘沁雨，常越，张文，张青，卢诚震，李海. GP73预测慢性乙型肝炎患者肝硬化进展研究. 武警医学. 2020(04): 317-323 . 百度学术
    27. 马玲玉，甄一宁，罗云萍，段昭君. gp73在小鼠肝纤维化肝组织中的表达及机制. 基础医学与临床. 2020(06): 771-776 . 百度学术
    28. 刘沁雨，常越，张青，丁玉平，李海. 血清GP73与PYGO2对已长期抗病毒治疗慢性乙型肝炎肝硬化的诊断价值. 山东医药. 2020(29): 64-66 . 百度学术
    29. 李佳娜，郑瑞琦，李娜，胡玉琳. 高尔基体蛋白73的生物学特征及在肝纤维化和肝硬化中的诊断价值. 临床肝胆病杂志. 2019(06): 1361-1364 . 本站查看
    30. 王春艳，纪冬，马丽君，陈松海，王晶晶，邵清，陈国凤，韩萍. 慢性乙型肝炎患者血清高尔基体蛋白73及其与肝脏炎症及纤维化的相关性. 解放军医学杂志. 2019(06): 503-507 . 百度学术
    31. 宋莹，李世朋，焦伟伟. 血清HMGB1、TGFβ1及GP73检测对脓毒症并发肝损伤预后的评估价值. 分子诊断与治疗杂志. 2019(06): 457-461 . 百度学术

    其他类型引用(12)

    • 资源附件(0)
  • 加载中
WeChat 本文二维码
计量
  • 文章访问数:  2284
  • HTML全文浏览量:  479
  • PDF下载量:  338
  • 被引次数: 43
出版历程
  • 收稿日期:  2021-07-19
  • 录用日期:  2021-08-31
  • 出版日期:  2021-11-20
  • 分享

    • 用微信扫码二维码

    分享至好友和朋友圈

目录

摘要
HTML全文
    参考文献(51)
    相关文章
    施引文献
    资源附件(0)

    /

    返回文章
    返回
        

    中国首个肝胆病专业杂志

    主管单位：中华人民共和国教育部

    主办单位：吉林大学

    学术支持：中华医学会肝病学分会

    通信地址：长春市新疆街461号

    投稿咨询：0431-88782044

    审稿咨询：0431-88783542

    电子信箱：lcgdb@vip.163.com

    关于本刊

    投稿指南

    在线期刊

    肝胆学院

    指南共识

    昨日IP[3692]昨日PV[7162]今日IP[4713]今日PV[9837]当前在线[69]

    网站设计 © 2020 《临床肝胆病杂志》编辑部 吉ICP备10000617号-1 技术支持: 仁和软件   百度统计